{"protocolSection": {"identificationModule": {"nctId": "NCT00842023", "orgStudyIdInfo": {"id": "ACCP-26060"}, "organization": {"fullName": "Western University of Health Sciences", "class": "OTHER"}, "briefTitle": "Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy", "officialTitle": "A Randomized Controlled Trial to Evaluate Renal Function, Inflammatory Mediators, and Neurohormonal Markers in Acutely Decompensated Heart Failure Patients Receiving Nesiritide Compared to Nitroglycerin.", "acronym": "ABC-HFT"}, "statusModule": {"statusVerifiedDate": "2013-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-07"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-02-10", "studyFirstSubmitQcDate": "2009-02-10", "studyFirstPostDateStruct": {"date": "2009-02-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-02-03", "resultsFirstSubmitQcDate": "2013-08-29", "resultsFirstPostDateStruct": {"date": "2013-08-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-08-29", "lastUpdatePostDateStruct": {"date": "2013-08-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Sheryl Chow", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "Western University of Health Sciences"}, "leadSponsor": {"name": "Western University of Health Sciences", "class": "OTHER"}, "collaborators": [{"name": "American College of Clinical Pharmacy", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.", "detailedDescription": "No additional details provided"}, "conditionsModule": {"conditions": ["Acute Decompensated Heart Failure"], "keywords": ["Natriuretic peptides", "BNP", "Heart Failure", "Nitoglycerin", "Biomarkers"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 89, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Nesiritide Infusion", "type": "EXPERIMENTAL", "description": "Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.", "interventionNames": ["Drug: Nesiritide"]}, {"label": "Nitroglycerin Infusion", "type": "ACTIVE_COMPARATOR", "description": "Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.", "interventionNames": ["Drug: Nitroglycerin"]}], "interventions": [{"type": "DRUG", "name": "Nesiritide", "description": "Bolus 2 mcg/kg followed by 0.01 mcg/kg/min", "armGroupLabels": ["Nesiritide Infusion"]}, {"type": "DRUG", "name": "Nitroglycerin", "description": "5-10 mcg/min titrating per protocol based on blood pressure", "armGroupLabels": ["Nitroglycerin Infusion"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Renal Function by Serum Creatinine", "description": "Serum creatinine values and changes in serum creatinine", "timeFrame": "Baseline, 24 hours, 48 hours"}], "otherOutcomes": [{"measure": "Inflammatory Markers", "description": "Interleukin-6", "timeFrame": "48 hours"}, {"measure": "Serum Levels of Cystatin-C", "description": "Cystatin-C is a protease inhibitor and a sensitive endogenous marker of renal function.", "timeFrame": "Baseline, 24 hours, 48 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* At least 18 years of age.\n* Subject must be able to understand the potential risks and benefits associated with the study.\n* Baseline systolic blood pressure \u2265 90 mm Hg at the time of enrollment.\n* Clinical symptoms of dyspnea and laboratory admission BNP levels \\> 500 pg/mL.\n* Neither pregnant or breastfeeding at the time of enrollment.\n* Authorization of patient's enrollment by patient's medical provider.\n\nExclusion Criteria:\n\n* \\<18 years of age\n* Denies written informed consent\n* Pregnant or lactating.\n* Baseline systolic BP \\< 90 mmHg or cardiogenic shock\n* No symptoms of congestion or admission BNP \\< 500 pg/mL\n* Known allergy to E.coli-derived products, or any history of anaphylactic reactions to nesiritide.\n* Receiving dialysis at the time of enrollment.\n* Serum creatinine \\> 2.5 mg/dL at the time of enrollment.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sheryl L. Chow, PharmD, FCCP, BCPS", "affiliation": "Western University of Heatlh Sciences", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Centinela Hospital Medical Center", "city": "Inglewood", "state": "California", "zip": "90301", "country": "United States", "geoPoint": {"lat": 33.96168, "lon": -118.35313}}]}, "referencesModule": {"references": [{"pmid": "21362524", "type": "RESULT", "citation": "Chow SL, O'Barr SA, Peng J, Chew E, Pak F, Quist R, Patel P, Patterson JH, Heywood JT. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure. J Card Fail. 2011 Mar;17(3):181-7. doi: 10.1016/j.cardfail.2010.10.005. Epub 2010 Dec 3."}, {"pmid": "21576282", "type": "RESULT", "citation": "Chow SL, O'Barr SA, Peng J, Chew E, Pak F, Quist R, Patel P, Patterson JH, Heywood JT. Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. Circ Heart Fail. 2011 Jul;4(4):450-5. doi: 10.1161/CIRCHEARTFAILURE.110.958066. Epub 2011 May 16."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Nesiritide Infusion", "description": "2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours."}, {"id": "FG001", "title": "Nitroglycerin Infusion", "description": "10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Nesiritide Infusion", "description": "2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours."}, {"id": "BG001", "title": "Nitroglycerin Infusion", "description": "10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "89"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "43"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68.6", "spread": "14.1"}, {"groupId": "BG001", "value": "66.8", "spread": "17.2"}, {"groupId": "BG002", "value": "67.7", "spread": "16.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "41"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "48"}]}]}]}, {"title": "Region of Enrollment", "description": "Sample size was estimated at 90 patients total; however, 1 patient was enrolled twice. Therefore, only 89 patients were enrolled in the primary study.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "89"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Renal Function by Serum Creatinine", "description": "Serum creatinine values and changes in serum creatinine", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, 24 hours, 48 hours", "groups": [{"id": "OG000", "title": "Nesiritide", "description": "2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours."}, {"id": "OG001", "title": "Nitroglycerin", "description": "10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"title": "Serum creatinine at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "0.4"}, {"groupId": "OG001", "value": "1.3", "spread": "0.4"}]}]}, {"title": "Serum creatinine at 24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "0.4"}, {"groupId": "OG001", "value": "1.4", "spread": "0.4"}]}]}, {"title": "Serum creatinine at 48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "0.4"}, {"groupId": "OG001", "value": "1.4", "spread": "0.5"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Inflammatory Markers", "description": "Interleukin-6", "populationDescription": "Only participants with available data were assessed for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pg/mL", "timeFrame": "48 hours", "groups": [{"id": "OG000", "title": "Nesiritide Infusion", "description": "2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours."}, {"id": "OG001", "title": "Nitroglycerin Infusion", "description": "10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25", "spread": "7"}, {"groupId": "OG001", "value": "50", "spread": "5"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Serum Levels of Cystatin-C", "description": "Cystatin-C is a protease inhibitor and a sensitive endogenous marker of renal function.", "populationDescription": "Only participants with available data were assessed for this outcome measure.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-07", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, 24 hours, 48 hours", "groups": [{"id": "OG000", "title": "Nesiritide", "description": "2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours."}, {"id": "OG001", "title": "Nitroglycerin", "description": "10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"title": "Cystatin-C at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1332", "spread": "1308"}, {"groupId": "OG001", "value": "2026", "spread": "1814"}]}]}, {"title": "Cystatin-C at 24 Hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "1475", "spread": "1291"}, {"groupId": "OG001", "value": "3108", "spread": "3761"}]}]}, {"title": "Cystatin-C at 48 Hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "1449", "spread": "1298"}, {"groupId": "OG001", "value": "2739", "spread": "3369"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "2 years", "eventGroups": [{"id": "EG000", "title": "Nesiritide Infusion", "description": "2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.", "seriousNumAffected": 12, "seriousNumAtRisk": 45, "otherNumAffected": 0, "otherNumAtRisk": 45}, {"id": "EG001", "title": "Nitroglycerin Infusion", "description": "10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP\\<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.", "seriousNumAffected": 12, "seriousNumAtRisk": 44, "otherNumAffected": 0, "otherNumAtRisk": 44}], "seriousEvents": [{"term": "Symptomatic Hypotension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 45}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 44}]}, {"term": "Death", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Assessed at 6 months", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 45}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 44}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Sheryl L. Chow", "organization": "Western University of Health Sciences", "email": "schow@westernu.edu", "phone": "9094695379"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M29439", "name": "Cardio-Renal Syndrome", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000020097", "term": "Natriuretic Peptide, Brain"}, {"id": "D000005996", "term": "Nitroglycerin"}], "ancestors": [{"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M21935", "name": "Natriuretic Peptide, Brain", "asFound": "Gastrocnemius", "relevance": "HIGH"}, {"id": "M9102", "name": "Nitroglycerin", "asFound": "RSV", "relevance": "HIGH"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}